Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial
Hjalmar Flygt(Uppsala University Hospital), Ulla Olsson‐Strömberg(Uppsala University Hospital), Berit Markevärn, Lydia Roy(Centre Hospitalier Universitaire de Poitiers), Satu Mustjoki(University of Helsinki), Susanne Saußele(University of Mannheim), Stina Söderlund(Unknown), Jeroen J. W. M. Janssen(Radboud University Nijmegen), Andreja Dimitrijevic(Odense University Hospital), Dominik Wolf(Universität Innsbruck), Perttu Koskenvesa(Helsinki University Hospital), Arta Dreimane(Linköping University Hospital), Bjørn Tore Gjertsen(Haukeland University Hospital), Henrik Hjorth‐Hansen(Norwegian University of Science and Technology), Johan Richter(Skåne University Hospital), Tobias Gedde‐Dahl, Waleed Majeed(Stavanger University Hospital), Jesper Stentoft(Aarhus University Hospital), Erik Ahlstrand(Örebro University), Leif Stenke(Karolinska University Hospital)
Cited by 13
Related Papers
International nosology of heritable disorders of connective tissue, Berlin, 1986
|American Journal of Medical Genetics|1988|733
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
|Blood|2013|632
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464